The role of myeloperoxidase as a diagnostic and prognostic factor in cardiovascular pathology (acute coronary syndrome)
DOI:
https://doi.org/10.14739/2310-1237.2021.2.235805Keywords:
myeloperoxidase, acute coronary syndrome, myocardial infarction, restenosis, cardiovascular pathology, prognosis, risk stratificationAbstract
Myeloperoxidase is one of the key enzymes involved in oxidative stress and inflammation. Its elevated levels are determined in a wide range of both acute and chronic forms of cardiovascular diseases. The inflammation results in the release of the enzyme from the white blood cells to form products such as hypochlorous acid, which in turn can have a negative effect on the target proteins. Inconsistent evidence on the predictive role of this biomarker in diseases of the circulatory system generates scientific interest and provokes further research in this direction.
The aim of this review is to analyze the scientific literature data on myeloperoxidase as a possible clinical use for the diagnosis and risk stratification of patients with саrdiovascular diseases.
Materials and methods. Searching and generalization of data from leading specialized sources, which are indexed by scientific databases PubMed, SCOPUS, Web of Science.
Results. The results of the studies indicate that myeloperoxidase is actively involved in the pathophysiology of cardiovascular diseases through participation in oxidative stress and inflammation, excessive production of proatherogenic lipoproteins, changes in nitric oxide activity, endothelial dysfunction, and due to the effect on the instability of atherosclerotic plaques. In patients with cardiovascular diseases, including ischemic heart disease, the concentration of the indicated protein is increased and is often associated with a poor prognosis, including an increased risk of mortality. Myeloperoxidase metabolites are often the factors that contribute to cell damage under conditions of ischemia. The review also considers the relationship of the enzyme with the development of restenosis and the effectiveness of revascularization after percutaneous coronary intervention.
Conclusions. The presented data mainly define myeloperoxidase as a significant marker for predicting long-term follow-up results and the development of serious adverse cardiovascular events, mortality in patients with cardiovascular disease. At the same time, despite the great achievements in disclosing the complex effects of myeloperoxidase, inconsistency in the available results is noteworthy. This controversy necessitates further research to elucidate and reveal the full clinical potential of myeloperoxidase in patients with cardiovascular pathology.
References
Stewart, J., Manmathan, G., & Wilkinson, P. (2017). Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. JRSM cardiovascular disease, 6, 2048004016687211. https://doi.org/10.1177/2048004016687211
Odobasic, D., Kitching, A. R., & Holdsworth, S. R. (2016). Neutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of Myeloperoxidase. Journal of immunology research, 2016, 2349817. https://doi.org/10.1155/2016/2349817
Gellhaar, S., Sunnemark, D., Eriksson, H., Olson, L., & Galter, D. (2017). Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease. Cell and tissue research, 369(3), 445-454. https://doi.org/10.1007/s00441-017-2626-8
Maki, R. A., Holzer, M., Motamedchaboki, K., Malle, E., Masliah, E., Marsche, G., & Reynolds, W. F. (2019). Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment. Free radical biology & medicine, 141, 115-140. https://doi.org/10.1016/j.freeradbiomed.2019.05.033
Thai, T., Zhong, F., Dang, L., Chan, E., Ku, J., Malle, E., Geczy, C. L., Keaney, J. F., Jr, & Thomas, S. R. (2021). Endothelial-transcytosed myeloperoxidase activates endothelial nitric oxide synthase via a phospholipase C-dependent calcium signaling pathway. Free radical biology & medicine, 166, 255-264. https://doi.org/10.1016/j.freeradbiomed.2020.12.448
Abdo, A. I., Rayner, B. S., van Reyk, D. M., & Hawkins, C. L. (2017). Low-density lipoprotein modified by myeloperoxidase oxidants induces endothelial dysfunction. Redox biology, 13, 623-632. https://doi.org/10.1016/j.redox.2017.08.004
Love, D. T., Barrett, T. J., White, M. Y., Cordwell, S. J., Davies, M. J., & Hakins, C. L. (2016). Cellular targets of the myeloperoxidase-derived oxidant hpothiocyanous acid (HOSCN) and its role in the inhibition of glycolysis in macrophages. Free radical biology & medicine, 94, 88-98. https://doi.org/10.1016/j.freeradbiomed.2016.02.016
Aratani Y. (2018). Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Archives of biochemistry and biophysics, 640, 47-52. https://doi.org/10.1016/j.abb.2018.01.004
Ndrepepa G. (2019). Myeloperoxidase - A bridge linking inflammation and oxidative stress with cardiovascular disease. Clinica chimica acta; international journal of clinical chemistry, 493, 36-51. https://doi.org/10.1016/j.cca.2019.02.022
Khan, A. A., Alsahli, M. A., & Rahmani, A. H. (2018). Myeloperoxidase as an Active Disease Biomarker: Recent Biochemical and Pathological Perspectives. Medical sciences, 6(2), 33. https://doi.org/10.3390/medsci6020033
Strzepa, A., Pritchard, K. A., & Dittel, B. N. (2017). Myeloperoxidase: A new player in autoimmunity. Cellular immunology, 317, 1-8. https://doi.org/10.1016/j.cellimm.2017.05.002
Anatoliotakis, N., Deftereos, S., Bouras, G., Giannopoulos, G., Tsounis, D., Angelidis, C., Kaoukis, A., & Stefanadis, C. (2013). Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease. Current topics in medicinal chemistry, 13(2), 115-138. https://doi.org/10.2174/1568026611313020004
Baldus, S., Heeschen, C., Meinertz, T., Zeiher, A. M., Eiserich, J. P., Münzel, T., Simoons, M. L., Hamm, C. W., & CAPTURE Investigators (2003). Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 108(12), 1440-1445. https://doi.org/10.1161/01.CIR.0000090690.67322.51
Brennan, M. L., Penn, M. S., Van Lente, F., Nambi, V., Shishehbor, M. H., Aviles, R. J., Goormastic, M., Pepoy, M. L., McErlean, E. S., Topol, E. J., Nissen, S. E., & Hazen, S. L. (2003). Prognostic value of myeloperoxidase in patients with chest pain. The New England journal of medicine, 349(17), 1595-1604. https://doi.org/10.1056/NEJMoa035003
Calmarza, P., Lapresta, C., Martínez, M., Lahoz, R., & Povar, J. (2018). Utility of myeloperoxidase in the differential diagnosis of acute coronary syndrome. Archivos de cardiologia de Mexico, 88(5), 391-396. https://doi.org/10.1016/j.acmx.2017.11.003
Tang, W. H., Tong, W., Troughton, R. W., Martin, M. G., Shrestha, K., Borowski, A., Jasper, S., Hazen, S. L., & Klein, A. L. (2007). Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. Journal of the American College of Cardiology, 49(24), 2364-2370. https://doi.org/10.1016/j.jacc.2007.02.053
Avaliani, T., Talakvadze, T., & Tabagari, S. (2019). Prognostic value of plasma myeloperoxidase level's and echocardiographic determinants in chronic heart failure patients. Georgian medical news, (288), 55-60.
McLaughlin, K., Baczyk, D., Potts, A., Hladunewich, M., Parker, J. D., & Kingdom, J. C. (2017). Low Molecular Weight Heparin Improves Endothelial Function in Pregnant Women at High Risk of Preeclampsia. Hypertension, 69(1), 180-188. https://doi.org/10.1161/HYPERTENSIONAHA.116.08298
Ganz, P., Amarenco, P., Goldstein, L. B., Sillesen, H., Bao, W., Preston, G. M., Welch, K., & SPARCL Steering Committee (2017). Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke, 48(12), 3223-3231. https://doi.org/10.1161/STROKEAHA.117.017965
Correa, S., Pena-Esparragoza, J. K., Scovner, K. M., Waikar, S. S., & Mc Causland, F. R. (2020). Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study. American journal of kidney diseases, 76(1), 32-41. https://doi.org/10.1053/j.ajkd.2019.09.006
Ramachandra, C., Ja, K., Chua, J., Cong, S., Shim, W., & Hausenloy, D. J. (2020). Myeloperoxidase As a Multifaceted Target for Cardiovascular Protection. Antioxidants & redox signaling, 32(15), 1135-1149. https://doi.org/10.1089/ars.2019.7971
Govindarajan, S., Raghavan, V. M., & Rao, A. C. (2016). Plasma Myeloperoxidase and Total Sialic Acid as Prognostic Indicators in Acute Coronary Syndrome. Journal of clinical and diagnostic research : JCDR, 10(8), BC09-BC13. https://doi.org/10.7860/JCDR/2016/20715.8347
Liu, C., Xie, G., Huang, W., Yang, Y., Li, P., & Tu, Z. (2012). Elevated serum myeloperoxidase activities are significantly associated with the prevalence of ACS and High LDL-C levels in CHD patients. Journal of atherosclerosis and thrombosis, 19(5), 435-443. https://doi.org/10.5551/jat.9704
Omran, M. M., Zahran, F. M., Kadry, M., Belal, A., & Emran, T. M. (2018). Role of myeloperoxidase in early diagnosis of acute myocardial infarction in patients admitted with chest pain. Journal of immunoassay & immunochemistry, 39(3), 337-347. https://doi.org/10.1080/15321819.2018.1492423
Sawicki, M., Sypniewska, G., Kozinski, M., Gruszka, M., Krintus, M., Obonska, K., Pilaczynska-Cemel, M., & Kubica, J. (2011). Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. European journal of clinical investigation, 41(6), 667-671. https://doi.org/10.1111/j.1365-2362.2010.02457.x
Searle, J., Shih, J., Muller, R., Vollert, J. O., Müller, C., Danne, O., Datwyler, S., & Möckel, M. (2013). The role of myeloperoxidase (MPO) for prognostic evaluation in sensitive cardiac troponin I negative chest pain patients in the emergency department. European heart journal. Acute cardiovascular care, 2(3), 203-210. https://doi.org/10.1177/2048872613484688
Trentini, A., Rosta, V., Spadaro, S., Bellini, T., Rizzo, P., Vieceli Dalla Sega, F., Passaro, A., Zuliani, G., Gentili, V., Campo, G., & Cervellati, C. (2020). Development, optimization and validation of an absolute specific assay for active myeloperoxidase (MPO) and its application in a clinical context: role of MPO specific activity in coronary artery disease. Clinical chemistry and laboratory medicine, 58(10), 1749-1758. https://doi.org/10.1515/cclm-2019-0817
Tietge U. (2018). The impact of myeloperoxidase on HDL function in myocardial infarction. Current opinion in endocrinology, diabetes, and obesity, 25(2), 137-142. https://doi.org/10.1097/MED.0000000000000394
Fong, S. W., Few, L. L., See Too, W. C., Khoo, B. Y., Nik Ibrahim, N. N., Yahaya, S. A., Yusof, Z., Mohd Ali, R., Abdul Rahman, A. R., & Yvonne-Tee, G. B. (2015). Systemic and coronary levels of CRP, MPO, sCD40L and PlGF in patients with coronary artery disease. BMC research notes, 8, 679. https://doi.org/10.1186/s13104-015-1677-8
Tan, Y., Yang, S., Chen, R., Sheng, Z., Zhou, P., Liu, C., Zhao, H., Song, L., Li, J., Zhou, J., Chen, Y., & Yan, H. (2020). High Plasma Myeloperoxidase Is Associated with Plaque Erosion in Patients with ST-Segment Elevation Myocardial Infarction. Journal of cardiovascular translational research, 13(6), 908-915. https://doi.org/10.1007/s12265-020-10002-x
Khan, D. A., Sharif, M. S., & Khan, F. A. (2011). Diagnostic performance of high-sensitivity troponin T, myeloperoxidase, and pregnancy-associated plasma protein A assays for triage of patients with acute myocardial infarction. The Korean journal of laboratory medicine, 31(3), 172-178. https://doi.org/10.3343/kjlm.2011.31.3.172
Stankovic, S., Asanin, M., Trifunovic, D., Majkic-Singh, N., Ignjatovic, S., Mrdovic, I., Matic, D., Savic, L., Marinkovic, J., Ostojic, M., & Vasiljevic, Z. (2012). Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Clinical biochemistry, 45(7-8), 547-551. https://doi.org/10.1016/j.clinbiochem.2012.02.015
Mehta, M. D., Marwah, S. A., Ghosh, S., Shah, H., Trivedi, A., & Haridas, N. (2016). A Synergistic Role of Myeloperoxidase and High Sensitivity Troponin T in the Early Diagnosis of Acute Coronary Syndrome. Indian journal of clinical biochemistry : IJCB, 31(1), 75-80. https://doi.org/10.1007/s12291-015-0490-4
Sinning, C., Schnabel, R., Peacock, W. F., & Blankenberg, S. (2008). Up-and-coming markers: myeloperoxidase, a novel biomarker test for heart failure and acute coronary syndrome application?. Congestive heart failure (Greenwich, Conn.), 14(4 Suppl 1), 46-48. https://doi.org/10.1111/j.1751-7133.2008.tb00012.x
Peacock, W. F., Nagurney, J., Birkhahn, R., Singer, A., Shapiro, N., Hollander, J., Glynn, T., Nowak, R., Safdar, B., Miller, C., Peberdy, M., Counselman, F., Chandra, A., Kosowsky, J., Neuenschwander, J., Schrock, J., Plantholt, S., Lewandrowski, E., Wong, V., Kupfer, K., … Diercks, D. (2011). Myeloperoxidase in the diagnosis of acute coronary syndromes: the importance of spectrum. American heart journal, 162(5), 893-899. https://doi.org/10.1016/j.ahj.2011.08.017
Stamboul, K., Zeller, M., Rochette, L., Cottin, Y., Cochet, A., Leclercq, T., Porot, G., Guenancia, C., Fichot, M., Maillot, N., Vergely, C., & Lorgis, L. (2017). Relation between high levels of myeloperoxidase in the culprit artery and microvascular obstruction, infarct size and reverse remodeling in ST-elevation myocardial infarction. PloS one, 12(7), e0179929. https://doi.org/10.1371/journal.pone.0179929
Baldus, S., Heitzer, T., Eiserich, J. P., Lau, D., Mollnau, H., Ortak, M., Petri, S., Goldmann, B., Duchstein, H. J., Berger, J., Helmchen, U., Freeman, B. A., Meinertz, T., & Münzel, T. (2004). Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free radical biology & medicine, 37(6), 902-911. https://doi.org/10.1016/j.freeradbiomed.2004.06.003
Ndrepepa, G., Braun, S., Mehilli, J., von Beckerath, N., Schömig, A., & Kastrati, A. (2008). Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. European journal of clinical investigation, 38(2), 90-96. https://doi.org/10.1111/j.1365-2362.2007.01908.x
Goldmann, B. U., Rudolph, V., Rudolph, T. K., Holle, A. K., Hillebrandt, M., Meinertz, T., & Baldus, S. (2009). Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction. Free radical biology & medicine, 47(1), 79-83. https://doi.org/10.1016/j.freeradbiomed.2009.04.004
Rebeiz, A. G., Tamim, H. M., Sleiman, R. M., Abchee, A. G., Ibrahim, Z., Khoury, M. Y., Youhanna, S., Skouri, H. N., & Alam, S. E. (2011). Plasma myeloperoxidase concentration predicts the presence and severity of coronary disease in patients with chest pain and negative troponin-T. Coronary artery disease, 22(8), 553-558. https://doi.org/10.1097/MCA.0b013e32834c5e98
Kutter, D., Devaquet, P., Vanderstocken, G., Paulus, J. M., Marchal, V., & Gothot, A. (2000). Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta haematologica, 104(1), 10-15. https://doi.org/10.1159/000041062
Jordan, J. E., Zhao, Z. Q., & Vinten-Johansen, J. (1999). The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovascular research, 43(4), 860-878. https://doi.org/10.1016/s0008-6363(99)00187-x
Vinten-Johansen J. (2004). Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovascular research, 61(3), 481-497. https://doi.org/10.1016/j.cardiores.2003.10.011
Khalil, W., Abdelhamed, M. & Eldamanhory, A. (2021). Validity of QRS Configuration and Myeloperoxidase Level as Determinants of CAD Severity and Prognosis in Patients with STEMI. World Journal of Cardiovascular Diseases, 11, 82-97. https://doi:10.4236/wjcd.2021.111010
Meuwese, M. C., Stroes, E. S., Hazen, S. L., van Miert, J. N., Kuivenhoven, J. A., Schaub, R. G., Wareham, N. J., Luben, R., Kastelein, J. J., Khaw, K. T., & Boekholdt, S. M. (2007). Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. Journal of the American College of Cardiology, 50(2), 159-165. https://doi.org/10.1016/j.jacc.2007.03.033
Khine, H. W., Teiber, J. F., Haley, R. W., Khera, A., Ayers, C. R., & Rohatgi, A. (2017). Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study. Atherosclerosis, 263, 156-162. https://doi.org/10.1016/j.atherosclerosis.2017.06.007
Koch, C., Henrich, M., & Heidt, M. C. (2014). Sequential analysis of myeloperoxidase for prediction of adverse events after suspected acute coronary ischemia. Clinical cardiology, 37(12), 744-749. https://doi.org/10.1002/clc.22336
O'Donoghue, M. L., Morrow, D. A., Cannon, C. P., Jarolim, P., Desai, N. R., Sherwood, M. W., Murphy, S. A., Gerszten, R. E., & Sabatine, M. S. (2016). Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. Journal of the American Heart Association, 5(5), e002586. https://doi.org/10.1161/JAHA.115.002586
Oemrawsingh, R. M., Lenderink, T., Akkerhuis, K. M., Heeschen, C., Baldus, S., Fichtlscherer, S., Hamm, C. W., Simoons, M. L., Boersma, E., & CAPTURE investigators (2011). Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart (British Cardiac Society), 97(13), 1061-1066. https://doi.org/10.1136/hrt.2010.197392
Kacprzak, M., & Zielinska, M. (2016). Prognostic value of myeloperoxidase concentration in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. International journal of cardiology, 223, 452-457. https://doi.org/10.1016/j.ijcard.2016.07.258
Kaya, M. G., Yalcin, R., Okyay, K., Poyraz, F., Bayraktar, N., Pasaoglu, H., Boyaci, B., & Cengel, A. (2012). Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Texas Heart Institute journal, 39(4), 500-506.
Zelzer, S., Enko, D., Pilz, S., Tomaschitz, A., März, W., & Meinitzer, A. (2017). Myeloperoxidase, asymmetric dimethyl-arginine and the renin-angiotensin-aldosterone-system in cardiovascular risk patients: Cross-sectional findings from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clinical biochemistry, 50(13-14), 739-745. https://doi.org/10.1016/j.clinbiochem.2017.03.013
Liu, S. C., Yi, T. C., Weng, H. Y., Zhang, L., Li, Y. X., Mohetaboer, M., Zhang, Y., Jiang, J., Li, J. P., & Huo, Y. (2018). Prognostic value of myeloperoxidase concentration in patients with acute coronary syndrome. Chinese Journal of Cardiology, 46(4), 284-291. https://doi.org/10.3760/cma.j.issn.0253-3758.2018.04.007
Kimak, E., Zięba, B., Duma, D., & Solski, J. (2018). Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease. Lipids in health and disease, 17(1), 71. https://doi.org/10.1186/s12944-018-0718-4
Pek, J. H., Fook-Chong, S. M. C., Choo, J. C. J., Tan, C. H. C., Lin, Z., Chan, C. M., Yeo, C. P., & Lim S. H. (2019). Copeptin, myeloperoxidase and pro-adrenomedullin for acute coronary syndrome in patients with chronic kidney disease. Proceedings of Singapore Healthcare, 28(3), 173-183. https://doi.org/10.1177/2010105819843927
Cavusoglu, E., Ruwende, C., Eng, C., Chopra, V., Yanamadala, S., Clark, L. T., Pinsky, D. J., & Marmur, J. D. (2007). Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. The American journal of cardiology, 99(10), 1364-1368. https://doi.org/10.1016/j.amjcard.2006.12.060
Morrow, D. A., Sabatine, M. S., Brennan, M. L., de Lemos, J. A., Murphy, S. A., Ruff, C. T., Rifai, N., Cannon, C. P., & Hazen, S. L. (2008). Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. European heart journal, 29(9), 1096-1102. https://doi.org/10.1093/eurheartj/ehn071
Kalantar-Zadeh, K., Brennan, M. L., & Hazen, S. L. (2006). Serum myeloperoxidase and mortality in maintenance hemodialysis patients. American journal of kidney diseases, 48(1), 59-68. https://doi.org/10.1053/j.ajkd.2006.03.047
Roman, R. M., Camargo, P. V., Borges, F. K., Rossini, A. P., & Polanczyk, C. A. (2010). Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coronary artery disease, 21(3), 129-136. https://doi.org/10.1097/MCA.0b013e328333f50d
Wong, N. D., Gransar, H., Narula, J., Shaw, L., Moon, J. H., Miranda-Peats, R., Rozanski, A., Hayes, S. W., Thomson, L. E., Friedman, J. D., & Berman, D. S. (2009). Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC. Cardiovascular imaging, 2(9), 1093-1099. https://doi.org/10.1016/j.jcmg.2009.05.012
Mocatta, T. J., Pilbrow, A. P., Cameron, V. A., Senthilmohan, R., Frampton, C. M., Richards, A. M., & Winterbourn, C. C. (2007). Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. Journal of the American College of Cardiology, 49(20), 1993-2000. https://doi.org/10.1016/j.jacc.2007.02.040
Tang, W. H., Wu, Y., Nicholls, S. J., & Hazen, S. L. (2011). Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clinical chemistry, 57(1), 33-39. https://doi.org/10.1373/clinchem.2010.152827
Tang, W. H., Iqbal, N., Wu, Y., & Hazen, S. L. (2013). Usefulness of cardiac biomarker score for risk stratification in stable patients undergoing elective cardiac evaluation across glycemic status. The American journal of cardiology, 111(4), 465-470. https://doi.org/10.1016/j.amjcard.2012.10.027
Nicholls, S. J., Tang, W. H., Brennan, D., Brennan, M. L., Mann, S., Nissen, S. E., & Hazen, S. L. (2011). Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clinical chemistry, 57(12), 1762-1770. https://doi.org/10.1373/clinchem.2011.166827
Scharnagl, H., Kleber, M. E., Genser, B., Kickmaier, S., Renner, W., Weihrauch, G., Grammer, T., Rossmann, C., Winkelmann, B. R., Boehm, B. O., Sattler, W., März, W., & Malle, E. (2014). Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography--the LURIC study. International journal of cardiology, 174(1), 96-105. https://doi.org/10.1016/j.ijcard.2014.03.168
Kolodziej, A. R., Abo-Aly, M., Elsawalhy, E., Campbell, C., Ziada, K. M., & Abdel-Latif, A. (2019). Prognostic Role of Elevated Myeloperoxidase in Patients with Acute Coronary Syndrome: A Systemic Review and Meta-Analysis. Mediators of inflammation, 2019, 2872607. https://doi.org/10.1155/2019/2872607
Cheng, M., Cheng, M., & Wei, Q. (2020). Association of myeloperoxidase, homocysteine and high-sensitivity C-reactive protein with the severity of coronary artery disease and their diagnostic and prognostic value. Experimental and therapeutic medicine, 20(2), 1532-1540. https://doi.org/10.3892/etm.2020.8817
Teng, N., Maghzal, G. J., Talib, J., Rashid, I., Lau, A. K., & Stocker, R. (2017). The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox report, 22(2), 51-73. https://doi.org/10.1080/13510002.2016.1256119
Apple, F. S., Pearce, L. A., Chung, A., Ler, R., & Murakami, M. M. (2007). Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clinical chemistry, 53(5), 874-881. https://doi.org/10.1373/clinchem.2006.080192
Stefanescu, A., Braun, S., Ndrepepa, G., Koppara, T., Pavaci, H., Mehilli, J., Schömig, A., & Kastrati, A. (2008). Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. American heart journal, 155(2), 356-360. https://doi.org/10.1016/j.ahj.2007.10.017
Eggers, K. M., Dellborg, M., Johnston, N., Oldgren, J., Swahn, E., Venge, P., & Lindahl, B. (2010). Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clinical biochemistry, 43(3), 240-245. https://doi.org/10.1016/j.clinbiochem.2009.09.026
Scirica, B. M., Sabatine, M. S., Jarolim, P., Murphy, S. A., de Lemos, J. L., Braunwald, E., & Morrow, D. A. (2011). Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. European heart journal, 32(6), 697-705. https://doi.org/10.1093/eurheartj/ehq468
Rudolph, V., Keller, T., Schulz, A., Ojeda, F., Rudolph, T. K., Tzikas, S., Bickel, C., Meinertz, T., Münzel, T., Blankenberg, S., & Baldus, S. (2012). Diagnostic and prognostic performance of myeloperoxidase plasma levels compared with sensitive troponins in patients admitted with acute onset chest pain. Circulation. Cardiovascular genetics, 5(5), 561-568. https://doi.org/10.1161/CIRCGENETICS.111.962290
Quidim, A. V., Bruno, T. C., Lacerda Leocádio, P. C., Dos Reis Menta, P. L., Alvarez-Leite, J. I., Santos, I. S., Lotufo, P. A., Benseñor, I. M., & Goulart, A. C. (2018). Myeloperoxidase activity and acute coronary syndrome survival: long-term evaluation in the ERICO study. Biomarkers in medicine, 12(11), 1219-1229. https://doi.org/10.2217/bmm-2018-0110
Wang, J., Tan, G. J., Han, L. N., Bai, Y. Y., He, M., & Liu, H. B. (2017). Novel biomarkers for cardiovascular risk prediction. Journal of geriatric cardiology : JGC, 14(2), 135-150. https://doi.org/10.11909/j.issn.1671-5411.2017.02.008
Jiang, H., Zhang, H., Yang, Y., & Yang, X. (2020). Associations of myeloperoxidase, interleukin-17A and heparin-binding EGF-like growth factor levels with in-stent restenosis after percutaneous coronary intervention: a single-centre case-control study in China. BMJ open, 10(11), e039405. https://doi.org/10.1136/bmjopen-2020-039405
Kukreja, N., Onuma, Y., Garcia-Garcia, H. M., Daemen, J., van Domburg, R., Serruys, P. W., & Interventional Cardiologists of the Thoraxcenter (2000 to 2005) (2009). The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC. Cardiovascular interventions, 2(6), 534-541. https://doi.org/10.1016/j.jcin.2009.04.003
Ikata, J., Wakatsuki, T., Oishi, Y., Oki, T., & Ito, S. (2000). Leukocyte counts and concentrations of soluble adhesion molecules as predictors of coronary atherosclerosis. Coronary artery disease, 11(6), 445-449. https://doi.org/10.1097/00019501-200009000-00001
Miyauchi, K., Kasai, T., Yokayama, T., Aihara, K., Kurata, T., Kajimoto, K., Okazaki, S., Ishiyama, H., & Daida, H. (2008). Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model. Circulation journal, 72(5), 832-838. https://doi.org/10.1253/circj.72.832
Kornowski, R., Hong, M. K., Tio, F. O., Bramwell, O., Wu, H., & Leon, M. B. (1998). In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. Journal of the American College of Cardiology, 31(1), 224-230. https://doi.org/10.1016/s0735-1097(97)00450-6
Torrado, J., Buckley, L., Durán, A., Trujillo, P., Toldo, S., Valle Raleigh, J., Abbate, A., Biondi-Zoccai, G., & Guzmán, L. A. (2018). Restenosis, Stent Thrombosis, and Bleeding Complications: Navigating Between Scylla and Charybdis. Journal of the American College of Cardiology, 71(15), 1676-1695. https://doi.org/10.1016/j.jacc.2018.02.023
Libby, P., Okamoto, Y., Rocha, V. Z., & Folco, E. (2010). Inflammation in atherosclerosis: transition from theory to practice. Circulation journal, 74(2), 213-220. https://doi.org/10.1253/circj.cj-09-0706
Tiyerili, V., Camara, B., Becher, M. U., Schrickel, J. W., Lütjohann, D., Mollenhauer, M., Baldus, S., Nickenig, G., & Andrié, R. P. (2016). Neutrophil-derived myeloperoxidase promotes atherogenesis and neointima formation in mice. International journal of cardiology, 204, 29-36. https://doi.org/10.1016/j.ijcard.2015.11.128
Oyenuga, A. O., Couper, D., Matsushita, K., Boerwinkle, E., & Folsom, A. R. (2018). Association of monocyte myeloperoxidase with incident cardiovascular disease: The Atherosclerosis Risk in Communities Study. PloS one, 13(10), e0205310. https://doi.org/10.1371/journal.pone.0205310
Ismael, F. O., Barrett, T. J., Sheipouri, D., Brown, B. E., Davies, M. J., & Hawkins, C. L. (2016). Role of Myeloperoxidase Oxidants in the Modulation of Cellular Lysosomal Enzyme Function: A Contributing Factor to Macrophage Dysfunction in Atherosclerosis?. PloS one, 11(12), e0168844. https://doi.org/10.1371/journal.pone.0168844
Pleva, L., Kusnierova, P., Plevova, P., Zapletalova, J., Karpisek, M., Faldynova, L., Kovarova, P., & Kukla, P. (2015). Increased levels of MMP-3, MMP-9 and MPO represent predictors of in-stent restenosis, while increased levels of ADMA, LCAT, ApoE and ApoD predict bare metal stent patency. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 159(4), 586-594. https://doi.org/10.5507/bp.2015.037
Claessen, B. E., Stone, G. W., Mehran, R., Witzenbichler, B., Brodie, B. R., Wöhrle, J., Witkowski, A., Guagliumi, G., Zmudka, K., Henriques, J. P., Tijssen, J. G., Sanidas, E. A., Chantziara, V., Hakim, D., Leon, S., Xu, K., & Dangas, G. D. (2012). Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. Journal of thrombosis and thrombolysis, 34(2), 165-179. https://doi.org/10.1007/s11239-012-0706-x
Ramirez, G. A., Yacoub, M. R., Ripa, M., Mannina, D., Cariddi, A., Saporiti, N., Ciceri, F., Castagna, A., Colombo, G., & Dagna, L. (2018). Eosinophils from Physiology to Disease: A Comprehensive Review. BioMed research international, 2018, 9095275. https://doi.org/10.1155/2018/9095275
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
